Roach et al. 4 investigated the correlation of PD-L1 status with the clinical outcome in a phase 1 clinical trial (KEYNOTE-001), and found that PD-L1 expression in more than 50% of tumor cells correlated with 41% overall response rate to pembrolizumab. The gene discussed is CD274; the disease is neoplasm.